fda warning letter semaglutide october 2025 The sent a to the maker of Ozempic and Wegovy over unreported potential GLP-1 side effects. Here's what to know September 8, 2025: FDA launches

Tirzepatide and which one may be the best option

Specific legislation may require us to retain certain data for a longer or shorter period

Insurance Exclusions and Prior Authorization Create Access Barriers Many insurance plans classify GLP-1 medications as non-essential weight loss drugs and exclude them entirely or require prior authorization tied to strict BMI thresholds

"Making efforts to stay hydrated may help offset some of the unpleasant oral symptoms." Another theory, based on recent studies in the journal Cureus, is that patients may experience a condition called dysaesthesia, Imaeda said, or a burning, tingling feeling "that can happen anywhere on the skin." The Cleveland Clinic defines the condition as a burning, crawling, piercing or electric sensation